HC Wainwright Issues Optimistic Forecast for ASMB Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – HC Wainwright lifted their Q1 2025 earnings per share estimates for Assembly Biosciences in a note issued to investors on Monday, March 24th. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of ($1.54) for the quarter, up from their prior estimate of ($1.95). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS and FY2028 earnings at ($12.32) EPS.

Several other research analysts have also weighed in on ASMB. StockNews.com lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday. Guggenheim started coverage on Assembly Biosciences in a report on Tuesday. They set a “buy” rating and a $31.00 price objective on the stock.

Assembly Biosciences Stock Up 0.8 %

Shares of NASDAQ ASMB opened at $10.90 on Wednesday. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93. The stock has a market cap of $81.78 million, a price-to-earnings ratio of -1.62 and a beta of 0.62. The company’s fifty day moving average is $12.63 and its 200-day moving average is $14.99.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The business had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Man Group plc bought a new stake in Assembly Biosciences during the 4th quarter worth about $309,000. B Group Inc. acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at about $799,000. Gilead Sciences Inc. bought a new stake in Assembly Biosciences during the fourth quarter worth about $34,865,000. Marshall Wace LLP boosted its position in Assembly Biosciences by 16.5% during the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 2,098 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Assembly Biosciences by 44.3% in the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock valued at $1,495,000 after purchasing an additional 29,087 shares in the last quarter. Institutional investors own 19.92% of the company’s stock.

Insider Buying and Selling

In other Assembly Biosciences news, Director Michael Houghton acquired 3,202 shares of the stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the acquisition, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is currently owned by company insiders.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.